Template:Percutaneous Coronary Intervention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(13 intermediate revisions by 4 users not shown)
Line 3: Line 3:
| colspan="1" style="text-align:center; background:DarkGray" |
| colspan="1" style="text-align:center; background:DarkGray" |


'''Percutaneous Coronary Intervention Microchapters
'''Percutaneous Coronary Intervention Guidelines Microchapters
'''
'''
|- bgcolor="LightGrey"
|- bgcolor="LightGrey"
Line 25: Line 25:
|-  
|-  
!
!
|- bgcolor="CadetBlue"
|- bgcolor="CadetBlue"
!
!
Guideline Recommendations
PCI Approaches:
|-  
|-
!
!
 
|- bgcolor="CadetBlue"
|- bgcolor="PaleTurquoise"
!
!
CAD Revascularization:
CAD Revascularization:
Line 47: Line 45:
!
!
::[[Percutaneous coronary intervention left main coronary artery disease|Left Main Coronary Artery Disease]]
::[[Percutaneous coronary intervention left main coronary artery disease|Left Main Coronary Artery Disease]]
|-
!
|- bgcolor="PaleTurquoise"
!
:::[[Intervention in left main coronary artery disease]]
|-  
|-  
!
!
Line 74: Line 78:
!
!


|- bgcolor="PaleTurquoise"
|- bgcolor="CadetBlue"
!
!
Pre-procedural Considerations:
Pre-procedural Considerations:
|-
|-
!
|- bgcolor="PaleTurquoise"
!
::[[Percutaneous coronary intervention radiation safety|Radiation Safety]]
|-
!
!


Line 116: Line 114:
!
!


|- bgcolor="PaleTurquoise"
|- bgcolor="CadetBlue"
!
!
Procedural Considerations:
Procedural Considerations:
Line 221: Line 219:
!
!
:[[Percutaneous coronary intervention revascularization before non-cardiac surgery|Revascularization Before Non-cardiac Surgery]]
:[[Percutaneous coronary intervention revascularization before non-cardiac surgery|Revascularization Before Non-cardiac Surgery]]
|-
!
|- bgcolor="PaleTurquoise"
!
:[[Percutaneous coronary intervention coronary stents|Coronary Stents]]
|-
|-
!
!
Line 299: Line 291:
!
!
::[[Percutaneous coronary intervention oral antiplatelet therapy|Oral Antiplatelet Therapy]]
::[[Percutaneous coronary intervention oral antiplatelet therapy|Oral Antiplatelet Therapy]]
|-
!
|- bgcolor="PaleTurquoise"
!
::[[Percutaneous coronary intervention Glycoprotein IIb/IIIa Receptor Antagonists|Glycoprotein IIb/IIIa Receptor Antagonists]]
|-
|-
!
!
Line 328: Line 326:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
::Anticoagulant Therapy:
:Anticoagulant Therapy:
|-
|-
!
!
Line 370: Line 368:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
::PCI in Specific Anatomic Situations:
:PCI in Specific Anatomic Situations:
|-
|-
!
!
Line 406: Line 404:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
::PCI in Specific Patient Populations:
:PCI in Specific Patient Populations:
|-
|-
!
!
Line 428: Line 426:
!
!


|- bgcolor="PaleTurquoise"
|- bgcolor="CadetBlue"
!
!
Post-Procedural Considerations:
Post-Procedural Considerations:
Line 436: Line 434:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
:[[Percutaneous coronary intervention post-procedural antiplatelet therapy|Post-procedural Antiplatelet Therapy:]]
:[[Percutaneous coronary intervention post-procedural antiplatelet therapy|Post-procedural Antiplatelet Therapy]]
|-
|-
!
!
Line 442: Line 440:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
::[[Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy|Proton Pump Inhibitors and Antiplatelet Therapy]]
:[[Percutaneous coronary intervention proton pump inhibitors and anti-platelet therapy|Proton Pump Inhibitors and Antiplatelet Therapy]]
|-
|-
!
!
Line 448: Line 446:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
::[[Percutaneous coronary intervention clopidogrel genetic testing|Clopidogrel Genetic Testing]]
:[[Percutaneous coronary intervention clopidogrel genetic testing|Clopidogrel Genetic Testing]]
|-
|-
!
!
Line 454: Line 452:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
::[[Percutaneous coronary intervention platelet function testing|Platelet Function Testing]]
:[[Percutaneous coronary intervention platelet function testing|Platelet Function Testing]]
|-
|-
!
!
Line 460: Line 458:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
:[[Percutaneous coronary intervention restenosis|Restenosis:]]
:[[Percutaneous coronary intervention restenosis|Restenosis]]
|-
|-
!
!
Line 466: Line 464:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
::[[Percutaneous coronary intervention exercise testing|Exercise Testing]]
:[[Percutaneous coronary intervention exercise testing|Exercise Testing]]
|-
|-
!
!
Line 472: Line 470:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
::[[Percutaneous coronary intervention cardiac rehabilitation|Cardiac Rehabilitation]]
:[[Percutaneous coronary intervention cardiac rehabilitation|Cardiac Rehabilitation]]
|-
|-
!
!


|- bgcolor="PaleTurquoise"
|- bgcolor="CadetBlue"
!
!
Quality and Performance Considerations:
Quality and Performance Considerations:

Latest revision as of 13:16, 21 June 2022

Percutaneous Coronary Intervention Guidelines Microchapters

Home

Patient Information

Overview

PCI Approaches:

CAD Revascularization:

Heart Team Approach to Revascularization Decisions
Left Main Coronary Artery Disease
Intervention in left main coronary artery disease
Non-Left Main Coronary Artery Disease
Revascularization to Improve Symptoms
Dual Antiplatelet Therapy Compliance and Stent Thrombosis
Hybrid Coronary Revascularization

Pre-procedural Considerations:

Contrast-Induced Acute Kidney Injury
Anaphylactoid Reactions
Statin Treatment
Bleeding Risk
Role of Onsite Surgical Backup

Procedural Considerations:

Vascular Access
PCI in Specific Clinical Situations:
Asymptomatic Ischemia or CCS Class I or II Angina
CCS Class III Angina
Unstable Angina/Non–ST-Elevation Myocardial Infarction
ST-Elevation Myocardial Infarction:
General and Specific Considerations
Coronary Angiography Strategies in STEMI
Primary PCI of the Infarct Artery
Delayed or Elective PCI in patients with STEMI
Fibrinolytic-Ineligible Patients
Facilitated PCI
Rescue PCI
After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion
Cardiogenic Shock
Prior Coronary Bypass Surgery
Revascularization Before Non-cardiac Surgery
Adjunctive Diagnostic Devices:
Fractional Flow Reserve
Intravascular Ultrasound
Adjunctive Therapeutic Devices:
Coronary Atherectomy
Thrombectomy
Laser Angioplasty
Cutting Balloon Angioplasty
Embolic Protection Devices
Percutaneous Hemodynamic Support Devices
Antiplatelet therapy:
Oral Antiplatelet Therapy
Glycoprotein IIb/IIIa Receptor Antagonists
Intravenous Antiplatelet therapy:
STEMI
UA/NSTEMI
SIHD
Anticoagulant Therapy:
Parenteral Anticoagulants During PCI
Unfractionated Heparin
Enoxaparin
Bivalirudin and Argatroban
Fondaparinux
No-Reflow Pharmacological Therapies
PCI in Specific Anatomic Situations:
Chronic Total Occlusions
Saphenous Vein Grafts
Bifurcation Lesions
Aorto-Ostial Stenoses
Calcified Lesions
PCI in Specific Patient Populations:
Chronic Kidney Disease
Peri-procedural Myocardial Infarction Assessment
Vascular Closure Devices

Post-Procedural Considerations:

Post-procedural Antiplatelet Therapy
Proton Pump Inhibitors and Antiplatelet Therapy
Clopidogrel Genetic Testing
Platelet Function Testing
Restenosis
Exercise Testing
Cardiac Rehabilitation

Quality and Performance Considerations:

Quality and Performance
Certification and Maintenance of Certification
Operator and Institutional Competency and Volume

Percutaneous Coronary Intervention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Percutaneous Coronary Intervention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Percutaneous Coronary Intervention

CDC on Percutaneous Coronary Intervention

Percutaneous Coronary Intervention in the news

Blogs on Percutaneous Coronary Intervention

Directions to Hospitals Treating Percutaneous Coronary Intervention

Risk calculators and risk factors for Percutaneous Coronary Intervention